Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.

By K. O’Connell, J. J. Wood, R. Wise, J. Lozier, M. Braun. Journal of the American Medical Association (JAMA), 2006

710 citations recorded by the source corpus.

Subfields: Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/46fa1a2b48f43013a1ce7082bd0eb217df98af1c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Donat R. Spahn

In Hematology

1. Donat R. Spahn

Citations in the corpus

• Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “8–24 %), likely due to the pro-coagulant state and thrombin burst associated with higher doses, though this is somewhat controversial [86, 110–112].”
• The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition (2019, background): “Indeed, the use of rFVIIa to treat traumatic coagulopathy represents an “off-label” indication and administration may increase the risk of thromboembolic complications [723].”
• Management of bleeding and coagulopathy following major trauma: an updated European guideline (2013, neutral): “boembolic complications [516].”